Tag: Nafithromycin

Developed over three decades of research, nafithromycin is a historic medical breakthrough as the first new antibiotic in its class to be introduced globally in over 30 years. This advanced ketolide is specifically designed to combat the growing threat of antimicrobial resistance, particularly in respiratory infections like pneumonia.

In recent years, the escalating threat of antimicrobial resistance has pushed pharmaceutical companies to innovate, leading to the development of powerful new antibiotics like nafithromycin. If you're wondering, "What is the brand name of nafithromycin?" the answer is Miqnaf, a breakthrough ketolide antibiotic created by the Indian pharmaceutical company Wockhardt. Launched to specifically address community-acquired bacterial pneumonia (CABP), Miqnaf represents a significant step forward in fighting drug-resistant infections.